Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil.

PURPOSE To determine the time-dependence of fluorouracil (5FU)-induced thymidylate synthase (TS) inhibition in colon cancer patients, the effect of leucovorin (LV), and the relation to response. PATIENTS AND METHODS A 5FU injection (500 mg/m2) was given to 47 patients with advanced colorectal cancer; tumor biopsy specimens were obtained 1 to 72 hours after laparotomy. Eleven patients received LV (2-hour infusion of 500 mg/m2) with 5FU midinfusion; biopsies were obtained after 45 hours. TS inhibition was evaluated by comparing the number of total and free 5-fluoro-2'-deoxy-uridine-5'- monophosphate (UMP) (FdUMP) binding sites and the total and residual catalytic activity of TS. RESULTS The total catalytic TS activity varied from 0 to 621 pmol/h/mg protein and the total number of FdUMP binding sites varied from 0 to 976 fmol/mg protein. The residual catalytic TS activity after 2, 23, and 45 hours was 41%, 65%, and 74% of the total catalytic activity; the number of free FdUMP binding sites was 12%, 27%, and 49% of the total number, respectively. LV enhanced TS inhibition after 45 hours; the residual catalytic activity decreased from 74% to 49%, and the number of free FdUMP binding sites from 49% to 24%. Eleven of 19 patients treated with hepatic arterial infusion of 5FU had a partial response (PR). In the nonresponding patients, total TS activity was significantly higher (P < .05) than in responding patients. A high TS activity with a poor inhibition correlated with no response. CONCLUSION Residual and total TS activity are predictive for response to 5FU. The findings may be applicable for treatment of patients with advanced disease and TS should be evaluated as a prognostic factor in adjuvant chemotherapy studies.

[1]  J. Bertino,et al.  Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. , 1993, Journal of the National Cancer Institute.

[2]  P. Johnston,et al.  Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. , 1993, Advances in experimental medicine and biology.

[3]  D. Martin,et al.  Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue. Correlation of antitumor activity with dosage and FUra incorporation into RNA. , 1992, Biochemical pharmacology.

[4]  Joseph,et al.  Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. , 1992, Cancer research.

[5]  K. Danenberg,et al.  Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. , 1992, Cancer research.

[6]  G. Peters,et al.  Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: enzyme activity and inhibition by 5-fluoro-2'-deoxy-uridine-5'-monophosphate. , 1991, European journal of cancer.

[7]  J. Bertino,et al.  Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. , 1990, Pharmacology & therapeutics.

[8]  S. Steinberg,et al.  Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Bernstein,et al.  Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. , 1988, Cancer research.

[10]  H. Pinedo,et al.  Fluorouracil: biochemistry and pharmacology. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  F. Berger,et al.  A naturally occurring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2'-deoxyuridine in a human colon tumor cell line. , 1988, Molecular pharmacology.

[12]  N. Petrelli,et al.  Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Houghton,et al.  Characterization of the pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in xenografts of human colon adenocarcinoma. , 1988, Cancer research.

[14]  P. Houghton,et al.  Determination of thymidylate synthase activity in colon tumor tissues after treatment with 5-fluorouracil. , 1987, Biochemical pharmacology.

[15]  G. Peters,et al.  Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. , 1986, Cancer research.

[16]  L. Johnson,et al.  Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. , 1985, Molecular pharmacology.

[17]  L. Johnson,et al.  Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines. , 1985, Molecular pharmacology.

[18]  L. Bernstein,et al.  Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. , 1984, Cancer research.

[19]  P. Danenberg,et al.  Human leukemic cells resistant to 5-fluoro-2'-deoxyuridine contain a thymidylate synthetase with lower affinity for nucleotides. , 1983, The Journal of biological chemistry.

[20]  C. Heidelberger,et al.  In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. , 1982, Cancer research.

[21]  D. Priest,et al.  Increased thymidylate synthetase in 5-fluorodeoxyuridine resistant cultured hepatoma cells. , 1980, Biochemical pharmacology.

[22]  P. Danenberg.  Thymidylate synthetase - a target enzyme in cancer chemotherapy. , 1977, Biochimica et biophysica acta.